tetano
Editor, Senior Moderator
Rev Med Virol
. 2021 Sep 24;e2295.
doi: 10.1002/rmv.2295. Online ahead of print.
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis
Jingwen Peng[SUP] 1 2 [/SUP], Meihua Fu[SUP] 1 2 [/SUP], Huan Mei[SUP] 1 2 [/SUP], Hailin Zheng[SUP] 1 2 [/SUP], Guanzhao Liang[SUP] 1 2 [/SUP], Xiaodong She[SUP] 1 2 [/SUP], Qiong Wang[SUP] 1 2 [/SUP], Weida Liu[SUP] 1 2 3 [/SUP]
Affiliations
Abstract
As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID-19) is becoming clearer and the potential for immunotherapy is increasing. However, clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) treatment in COVID-19 patients are not yet known. We searched PubMed, Embase Medline, Web of Science and MedRxiv using specific search terms in studies published from 1 January 2020 to 20 December 2020. In total, 33 studies, including 3073 cases and 6502 controls, were selected for meta-analysis. We found that immunosuppressant therapy significantly decreased mortality in COVID-19 patients on overall analysis (odds ratio = 0.71, 95% confidence interval = 0.57-0.89, p = 0.004). We also found that tocilizumab and anakinra significantly decreased mortality in patients without any increased risk of secondary infection. In addition, we found similar results in several subgroups. However, we found that tocilizumab therapy significantly increased the risk of fungal co-infections in COVID-19 patients. This represents the only systematic review and meta-analysis to investigate the efficacy and secondary infection risk of immunosuppressant treatment in COVID-19 patients. Overall, immunosuppressants significantly decreased mortality but had no effect on increased risk of secondary infections. Our analysis of tocilizumab therapy showed a significantly increased risk of fungal co-infections in these patients.
Keywords: COVID-19; anakinra; meta-analysis; sarilumab; tocilizumab.
. 2021 Sep 24;e2295.
doi: 10.1002/rmv.2295. Online ahead of print.
Efficacy and secondary infection risk of tocilizumab, sarilumab and anakinra in COVID-19 patients: A systematic review and meta-analysis
Jingwen Peng[SUP] 1 2 [/SUP], Meihua Fu[SUP] 1 2 [/SUP], Huan Mei[SUP] 1 2 [/SUP], Hailin Zheng[SUP] 1 2 [/SUP], Guanzhao Liang[SUP] 1 2 [/SUP], Xiaodong She[SUP] 1 2 [/SUP], Qiong Wang[SUP] 1 2 [/SUP], Weida Liu[SUP] 1 2 3 [/SUP]
Affiliations
- PMID: 34558756
- DOI: 10.1002/rmv.2295
Abstract
As the pandemic progresses, the pathophysiology of coronavirus disease 2019 (COVID-19) is becoming clearer and the potential for immunotherapy is increasing. However, clinical efficacy and safety of immunosuppressants (including tocilizumab, sarilumab and anakinra) treatment in COVID-19 patients are not yet known. We searched PubMed, Embase Medline, Web of Science and MedRxiv using specific search terms in studies published from 1 January 2020 to 20 December 2020. In total, 33 studies, including 3073 cases and 6502 controls, were selected for meta-analysis. We found that immunosuppressant therapy significantly decreased mortality in COVID-19 patients on overall analysis (odds ratio = 0.71, 95% confidence interval = 0.57-0.89, p = 0.004). We also found that tocilizumab and anakinra significantly decreased mortality in patients without any increased risk of secondary infection. In addition, we found similar results in several subgroups. However, we found that tocilizumab therapy significantly increased the risk of fungal co-infections in COVID-19 patients. This represents the only systematic review and meta-analysis to investigate the efficacy and secondary infection risk of immunosuppressant treatment in COVID-19 patients. Overall, immunosuppressants significantly decreased mortality but had no effect on increased risk of secondary infections. Our analysis of tocilizumab therapy showed a significantly increased risk of fungal co-infections in these patients.
Keywords: COVID-19; anakinra; meta-analysis; sarilumab; tocilizumab.